| Bioactivity | GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia[1]. |
| Target | Encephalin convertase, Ki 值为8.8 nM. |
| Invitro | GEMSA inhibits the activation of TAFI and porcine CBB[1].GEMSA can inhibit the prolongation of lysis time in recombinant BAP and does not lead to the lysis of APC fibronectin[1].GEMSA inhibits the prolongation of lysis time in porcine CPB, TAFI, and recombinant BAP, APC with the EC50 values of 0.34 μM, 100μM, 115 μM, 90 μM respectively[1][2]. |
| In Vivo | GEMSA (ICV, 0.1μg/mg, every, 3days) results in a 75% increase in hypothalamic luteinizing hormone-releasing hormone and serum luteinizing hormone levels, and a 60% decrease in serum prolactin concentrations in rat[3] |
| Name | GEMSA |
| CAS | 77482-44-1 |
| Formula | C7H13N3O4S |
| Molar Mass | 235.26 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. B Przewlocka, et al. Analgesic and convulsant effects of guanidinoethylmercaptosuccinic acid (GEMSA)--a potent enkephalin convertase inhibitor. Neuropeptides. Nov-Dec 1986;8(4):359-65. |